A Phase 2/3, multicenter, randomized open-label study of zanzalintinib vs everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors

Status

Not yet recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521043-20-00

Acronym

XL092-311

Enrollment

172

Registered

2026-01-09

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuroendocrine tumors

Brief summary

Progression-free survival per RECIST 1.1 as assessed by blinded independent central review

Detailed description

1. Objective response rate per RECIST 1.1 as assessed by blinded independent central review, 2. Overall survival

Interventions

DRUGEVEROLIMUS

DRUGXL092

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression-free survival per RECIST 1.1 as assessed by blinded independent central review	—

Secondary

Measure	Time frame
1. Objective response rate per RECIST 1.1 as assessed by blinded independent central review, 2. Overall survival	—

Countries

Austria, Belgium, France, Germany, Italy, Netherlands, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026